Continuous infusion of antibiotics in the critically ill: The new holy grail for beta-lactams and vancomycin?

Annals of Intensive Care

Volumn 2, Issue 1, 2012, Pages

  van Herendael, Bruno ^a   Jeurissen, Axel ^b   Tulkens, Paul M ^c   Vlieghe, Erika ^a,d   Verbrugghe, Walter ^a   Jorens, Philippe G ^a   Ieven, Margareta ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b Sint Vincentiusziekenhuis   (Belgium)

^c UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^d INSTITUTE OF TROPICAL MEDICINE   (Belgium)

Author keywords

Antibiotic(s); Beta lactam; Continuous infusion; Critically ill; Intermittent infusion; Pharmacokinetic pharmacodynamic; Vancomycin

Indexed keywords

ACETYLCYSTEINE; AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CARBENICILLIN; CEFAMANDOLE; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CILASTATIN PLUS IMIPENEM; CLARITHROMYCIN; DORIPENEM; FLUCLOXACILLIN; LORAZEPAM; MEROPENEM; MIDAZOLAM; OXACILLIN; PENICILLIN DERIVATIVE; PENICILLIN G; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TEMOCILLIN; TOBRAMYCIN; UNINDEXED DRUG; VANCOMYCIN;

ABDOMINAL INFECTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; BACTEREMIA; BACTERIAL ENDOCARDITIS; BACTERIUM ISOLATE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; CONTINUOUS INFUSION; CRITICAL ILLNESS; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ENTEROBACTERIACEAE INFECTION; GRAM NEGATIVE BACTERIUM; HUMAN; IMMUNOCOMPROMISED PATIENT; INFECTION; INTENSIVE CARE UNIT; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MICROORGANISM; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NEUTROPENIA; NONHUMAN; PATHOGENESIS; PATIENT MONITORING; PHARMACODYNAMICS; PHARMACOLOGICAL PARAMETERS; PNEUMONIA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SEPSIS; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; SURVIVAL RATE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 84864237868     PISSN: None     EISSN: 21105820     Source Type: Journal    
DOI: 10.1186/2110-5820-2-22     Document Type: Review

References (84)

1. Carlet J, Collignon P, Goldmann D, Goossens H, Gyssens IC, Harbarth S, Jarlier V, Levy SB, N'doye B, Pittet D, Richtmann R, Seto WH, Van der Meer JW, Voss A: Society's failure to protect a precious resource: antibiotics. Lancet 2011, 378(9788):369-371.
2. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J: Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009, 48(1):1-12.
3. Craig WA: Pharmacokinetic/pharmacodynamic parameters: rationale for antibiotic dosing of mice and men. Clin Infect Dis 1998, 26:1-10.
4. Mouton JW, Vinks AA: Is continuous infusion of beta-lactam antibiotics worthwhile?-efficacy and pharmacokinetic considerations. J Antimicrob Chemother 1996, 38(1):5-15.
5. Mouton JW, Punt N, Vinks AA: Concentration-effect relationship of ceftazidime explains why the time above the MIC is 40 percent for a static effect in vivo. Antimicrob Agents Chemother 2007, 51(9):3449-3451.
6. Craig WA: Interrelationship between pharmacokinetics and pharmacodynamics in determining dosing regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 1995, 22:89-96.
7. Craig WA: Antimicrobial resistance issues of the future. Diagn Microbiol Infect Dis 1996, 25:213-217.
8. McKinnon PS, Paladino JA, Schentag JJ: Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T > MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents 2008, 31(4):345-351.
9. Mouton JW, den Hollander JG: Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 1994, 38(5):931-936.
10. Alou L, Aguilar L, Sevillano D, Giménez MJ, Echeverría O, Gómez-Lus ML, Prieto J: Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa: An in vitro pharmacodynamic model. J Antimicrob Chemother 2005, 55(2):209-213.
11. Lipman J, Gomersall CD, Gin T, Joynt GM, Young RJ: Continuous infusion ceftazidime in intensive care: a randomized controlled trial. J Antimicrob Chemother 1999, 43(2):309-311.
12. Jaruratanasirikul S, Sriwiriyajan S, Punyo J: Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection. Antimicrob Agents Chemother 2005, 49(4):1337-1339.
13. De Jongh R, Hens R, Basma V, Mouton JW, Tulkens PM, Carryn S: Continuous versus II of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. J Antimicrob Chemother 2008, 61(2):382-388.
14. Bulitta JB, Duffull SB, Kinzig-Schippers M, Holzgrabe U, Stephan U, Drusano GL, Sörgel F: Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers. Antimicrob Agents Chemother 2007, 51(7):2497-2507.
15. Roberts JA, Kirkpatrick CM, Roberts MS, Robertson TA, Dalley AJ, Lipman J: Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother 2009, 64(1):142-150.
16. Rafati MR, Rouini MR, Mojtahedzadeh M, Najafi A, Tavakoli H, Gholami K, Fazeli MR: Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients. Int J Antimicrob Agents 2006, 28(2):122-127.
17. Van Zanten AR, Oudijk M, Nohlmans-Paulssen MK, van der Meer YG, Girbes AR, Polderman KH: Continuous vs. intermittent cefotaxime administration in patients with chronic obstructive pulmonary disease and respiratory tract infections: pharmacokinetics/pharmacodynamics, bacterial susceptibility and clinical efficacy. Br J Clin Pharmacol 2007, 63(1):100-109.
18. Mariat C, Venet C, Jehl F, Mwewa S, Lazarevic V, Diconne E, Fonsale N, Carricajo A, Guyomarc'h S, Vermesch R, Aubert G, Bidault R, Bertrand JC, Zeni F: Continuous infusion of ceftazidime in critically ill patients undergoing continuous venovenous hemodiafiltration: pharmacokinetic evaluation and dose recommendation. Crit Care 2006, 10(1):R26.
19. Udy AA, Putt MT, Shanmugathasan S, Roberts JA, Lipman J: Augmented renal clearance in the Intensive Care Unit: an illustrative case series. Int J Antimicrob Agents 2010, 35(6):606-608.
20. Roberts JA, Lipman J: Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin Pharmacokinet 2006, 45(8):755-773.
21. Roosendaal R, Bakker-Woudenberg IA, Van den Berghe-Van Raffe M, den Berg JC Vink-Van, Michel BM: Impact of the dosage schedule on the efficacy of ceftazidime, gentamicin and ciprofloxacin in Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats. Eur J Clin Microbiol Infect Dis 1989, 8:878-887.
22. Roosendaal R, Bakker-Woudenberg IA, van den Berghe-van Raffe M, Michel MF: Continuous versus intermittent administration of ceftazidime in experimental Klebsiella pneumoniae pneumonia in normal and leukopenic rats. Antimicrob Agents Chemother 1986, 30:403-408.
23. Roosendaal R, Bakker-Woudenberg IA, van den Berg JC, Michel MF: Therapeutic efficacy of continuous versus intermittent administration of ceftazidime in an experimental Klebsiella pneumoniae pneumonia in rats. J Infect Dis 1985, 152:373-378.
24. Roosendaal R, Bakker-Woudenberg IA: Impact of the antibiotic dosage schedule on efficacy in experimental lung infections. Scand J Infect Dis 1990, 74:155-162.
25. Angus BJ, Smith MD, Suputtamongkol Y, Mattie H, Walsh AL, Wuthiekanun V, Chaowagul W, White NJ: Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis. Br J Clin Pharmacol 2000, 50:184-191.
26. Buijk SL, Gyssens IC, Mouton JW, Van Vliet A, Verbrugh HA, Bruining HA: Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infections. J Antimicrob Chemother 2002, 49(1):121-128.
27. Benko AS, Cappelletty DM, Kruse JA, Rybak MJ: Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gramnegative infections. Antimicrob Agents Chemother 1996, 40:691-695.
28. Hanes SD, Wood GC, Herring V, Croce MA, Fabian TC, Pritchard E, Boucher BA: Intermittent and continuous ceftazidime infusion for critically ill trauma patients. Am J Surg 2000, 179(6):436-440.
29. Boselli E, Breilh D, Rimmele T, et al: Plasma and lung concentrations of ceftazidime administered in continuous infusion to critically ill patients with severe nosocomial pneumonia. Intensive Care Med 2004, 30:989-991.
30. Jaruratanasirikul S, Sriwiriyajan S, Ingviya N: Continuous infusion versus intermittent administration of cefepime in patients with Gram-negative bacilli bacteraemia. J Pharm Pharmacol 2002, 54:1693-1696.
31. Boselli E, Breilh D, Duflo F, et al: Steady-state plasma and intrapulmonary concentrations of cefepime administered in continuous infusion in critically ill patients with severe nosocomial pneumonia. Crit Care Med 2003, 31:2102-2106.
32. Li C, Kuti JL, Nightingale CH, Mansfield DL, Dana A, Nicolau DP: Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection. J Antimicrob Chemother 2005, 56(2):388-395.
33. Roberts JA, Roberts MS, Dalley A, Cross SE, Lipman J: Exposure and predicted antimicrobial efficacy in critically ill patients: piperacillin. In The Society of Hospital Pharmacists of Australia: Queensland Branch Conference; 21-22 October 2006. Brisbane, Australia: SHPA; 2006.
34. Roberts JA, Webb S, Paterson D, Ho KM, Lipman J: A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics. Crit Care Med 2009, 37(6):2071-2078.
35. Roberts JA, Boots R, Rickard CM, Thomas P, Quinn J, Roberts DM, Richards B, Lipman J: Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care? A randomized controlled pilot study. J Antimicrob Chemother 2007, 59(2):285-291.
36. Bodey GP, Ketchel SJ, Rodriguez V: A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients. Am J Med 1979, 67(4):608-616.
37. Lagast H, Meunier-Carpentier F, Klastersky J: Treatment of gram-negative bacillary septicemia with cefoperazone. Eur J Clin Microbiol 1983, 2(6):554-558.
38. Nicolau DP, McNabb J, Lacy MK, Quintiliani R, Nightingale CH: Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. Int J Antimicrob Agents 2001, 17(6):497-504.
39. Pedeboscq S, Dubau B, Frappier S, Hernandez V, Veyssières D, Winnock S, Pometan JP: Comparison of 2 administration protocols (continuous or discontinuous) of a timedependent antibiotic, Tazocin. Pathol Biol 2001, 49:540-547.
40. Buck C, Bertram N, Ackermann T, Sauerbruch T, Derendorf H, Paar WD: Pharmacokinetics of piperacillin-tazobactam: Intermittent dosing versus continuous infusion. Int J Antimicrob Agents 2005, 25:62-67.
41. Georges B, Conil JM, Cougot P, Decun JF, Archambaud M, Seguin T, Chabanon G, Virenque C, Houin G, Saivin S: Cefepime in critically ill patients: Continuous infusion vs. an intermittent dosing regimen. Int J Clin Pharmacol Ther 2005, 43:360-369.
42. Lau WK, Mercer D, Itani KM, Nicolau DP, Kuti JL, Mansfield D, Dana A: Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection. Antimicrob Agents Chemother 2006, 50:3556-3561.
43. Kojika M, Sato N, Hakozaki M, Suzuki Y, Takahasi G, Endo S, Suzuki K, Wakabayasi G: A preliminary study of the administration of carbapenem antibiotics in sepsis patients on the basis of the administration time. Jpn J Antibiot 2005, 58(5):452-457.
44. Sakka SG, Glauner AK, Bulitta JB, Kinzig-Schippers M, Pfister W, Drusano GL, Sörgel F: Population pharmacokinetics and pharmacodynamics of continuous versus shortterm infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial. Antimicrob Agents Chemother 2007, 51:3304-3310.
45. Walton AL, Howden BP, Grayson LM, Korman TM: Continuous-infusion penicillin home-based therapy for serious infections due to penicillin-susceptible pathogens. Int J Antimicrob Agents 2007, 29(5):544-548.
46. Howden BP, Richards MJ: The efficacy of continuous infusion flucloxacillin in home therapy for serious staphylococcal infections and cellulitis. J Antimicrob Chemother 2001, 48(2):311-314.
47. Leder K, Turnidge JD, Korman TM, Grayson ML: The clinical efficacy of continuousinfusion flucloxacillin in serious staphylococcal sepsis. J Antimicrob Chemother 1999, 43(1):113-118.
48. Hughes DW, Frei CR, Maxwell PR, Green K, Patterson JE, Crawford GE, Lewis JS: Continuous versus intermittent infusion of oxacillin for treatment of infective endocarditis caused by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother 2009, 53(5):2014-2019.
49. Grant EM, Kuti JL, Nicolau DP, Nightingale C, Quintiliani R: Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital. Pharmacotherapy 2002, 22(4):471-483.
50. Lodise TP Jr, Lomaestro B, Drusano GL: Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 2007, 44(3):357-363.
51. Lorente L, Jiménez A, Martín MM, Iribarren JL, Jiménez JJ, Mora ML: Clinical cure of ventilator-associated pneumonia treated with piperacillin/tazobactam administered by continuous or intermittent infusion. Int J Antimicrob Agents 2009, 33(5):464-468.
52. Lorente L, Jiménez A, Palmero S, Jiménez JJ, Iribarren JL, Santana M, Martín MM, Mora ML: Comparison of clinical cure rates in adults with ventilator-associated pneumonia treated with intravenous ceftazidime administered by continuous or intermittent infusion: a retrospective, nonrandomized, open-label, historical chart review. Clin Ther 2007, 29(11):2433-2439.
53. Lorente L, Lorenzo L, Martín MM, Jiménez A, Mora ML: Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli. Ann Pharmacother 2006, 40(2):219-223.
54. Sakka SG, Glauner AK, Bulitta JB, Kinzig-Schippers M, Pfister W, Drusano GL, Sörgel F: Population pharmacokinetics and pharmacodynamics of continuous versus shortterm infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial. Antimicrob Agents Chemother 2007, 51(9):3304-3310.
55. Daikos GL, Markogiannakis A: Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems? Clin Microbiol Infect 2011, 17(8):1135-1141.
56. McNabb JJ, Nightingale CH, Quintiliani R, Nicolau DP: Cost-effectiveness of ceftazidime by continuous infusion versus intermittent infusion for nosocomial pneumonia. Pharmacotherapy 2001, 21(5):549-555.
57. Mouton JW, Vinks AA: Continuous infusion of beta-lactams. Curr Opin Crit Care 2007, 13(5):598-606.
58. Martin JH, Fay MF, Udy A, Roberts J, Kirkpatrick C, Ungerer J, Lipman J: Pitfalls of using estimations of glomerular filtration rate in an intensive care population. Intern Med J 2011, 41(7):537-543.
59. Taccone FS, Laterre PF, Dugernier T, Spapen H, Delattre I, Wittebole X, De Backer D, Layeux B, Wallemacq P, Vincent JL, Jacobs F: Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care 2010, 14(4):R126.
60. Viaene E, Chanteux H, Servais H, Mingeot-Leclercq MP, Tulkens PM: Comparative stability studies of antipseudomonal beta-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motoroperated syringes (intensive care units). Antimicrob Agents Chemother 2002, 46(8):2327-2332.
61. Vinks AA, Touw DJ, van Rossen RC, Heijerman HG, Bakker W: Stability of aztreonam in a portable pump reservoir used for home intravenous antibiotic treatment (HIVAT). Pharm World Sci 1996, 18(2):74-77.
62. Servais H, Tulkens PM: Stability and compatibility of ceftazidime administered by continuous infusion to intensive care patients. Antimicrob Agents Chemother 2001, 45(9):2643-2647.
63. Baririan N, Chanteux H, Viaene E, Servais H, Tulkens PM: Stability and compatibility study of cefepime in comparison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units. J Antimicrob Chemother 2003, 51(3):651-658.
64. Berthoin K, Le Duff CS, Marchand-Brynaert J, Carryn S, Tulkens PM: Stability of meropenem and doripenem solutions for administration by continuous infusion. J Antimicrob Chemother 2010, 65(5):1073-1075.
65. Trissel: Handbook on infectible drugs. 15th edition. Bethesda: America Society of Health System Pharmacists; 2009.
66. Vella-Brincat JW, Begg EJ, Gallagher K, Kirkpatrick CM, Zhang M, Frampton C, Chambers ST: Stability of benzylpenicillin during continuous home intravenous therapy. J Antimicrob Chemother 2004, 53(4):675-677.
67. Craig WA: Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am 2003, 17(3):479-501.
68. Ebert S: vivo cidal activity and pharmacokinetic parameters for vancomycin against methicillin-susceptible and-resistant S. aureus [abstract 439]. In Program and abstracts of the 27th Interscience Conference on Antimicrobial Agents and Chemotherapy (New York). Washington, DC: American Society for Microbiology; 1987:173.
69. thInterscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington: American Society for Microbiology; 1999:49.
70. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ: Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004, 43(13):925-942.
71. Rybak M, Lomaestro B, Rotschafer JC, Moellering R Jr, Craig W, Billeter M, Dalovisio JR, Levine DP: Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009, 66(1):82-98.
72. Wysocki M, Delatour F, Faurisson F, Rauss A, Pean Y, Misset B, Thomas F, Timsit JF, Similowski T, Mentec H, Mier L, Dreyfuss D: Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother 2001, 45(9):2460-2467.
73. Vuagnat A, Stern R, Lotthe A, Schuhmacher H, Duong M, Hoffmeyer P, Bernard L: High dose vancomycin for osteomyelitis: continuous vs. intermittent infusion. J Clin Pharm Ther 2004, 29(4):351-357.
74. Di Filippo A, De Gaudio AR, Novelli A, Paternostro E, Pelagatti C, Livi P, Novelli GP: Continuous infusion of vancomycin in methicillin-resistant staphylococcus infection. Chemotherapy 1998, 44(1):63-68.
75. Rello J, Sole-Violan J, Sa-Borges M, Garnacho-Montero J, Muñoz E, Sirgo G, Olona M, Diaz E: Pneumonia caused by oxacillin-resistant Staphylococcus aureus treated with glycopeptides. Crit Care Med 2005, 33(9):1983-1987.
76. Ingram PR, Lye DC, Fisher DA, Goh WP, Tam VH: Nephrotoxicity of continuous versus intermittent infusion of vancomycin in outpatient parenteral antimicrobial therapy. Int J Antimicrob Agents 2009, 34(6):570-574.
77. Hutschala D, Kinstner C, Skhirdladze K, Thalhammer F, Müller M, Tschernko E: Influence of vancomycin on renal function in critically ill patients after cardiac surgery: continuous versus intermittent infusion. Anesthesiology 2009, 111(2):356-365.
78. Byl B, Jacobs F, Wallemacq P, Rossi C, de Francquen P, Cappello M, Leal T, Thys JP: Vancomycin penetration of uninfected pleural fluid exudate after continuous or intermittent infusion. Antimicrob Agents Chemother 2003, 47(6):2015-2017.
79. Cataldo MA, Tacconelli E, Grilli E, Pea F, Petrosillo N: Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis. J Antimicrob Chemother 2012, 67(1):17-24.
80. Spapen HD, Janssen van Doorn K, Diltoer M, Verbrugghe W, Jacobs R, Dobbeleir N, Honoré PM, Jorens PG: Retrospective evaluation of possible renal toxicity associated with continuous infusion of vancomycin in critically ill patients. Ann Intensive Care 2011, 19(1):1-26.
81. Gupta A, Biyani M, Khaira A: Vancomycin nephrotoxicity: myths and facts. Neth J Med 2011, 69(9):379-383.
82. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, Rybak JM, Talan DA, Chambers HF: Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillinresistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011, 52(3):18-55.
83. Ingram PR, Lye DC, Tambyah PA, Goh WP, Tam VH, Fisher DA: Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy. J Antimicrob Chemother 2008, 62(1):168-171.
84. Jeurissen A, Sluyts I, Rutsaert R: A higher dose of vancomycin in continuous infusion is needed in critically ill patients. Int J Antimicrob Agents 2011, 37(1):75-77.